Some of these include: Hypoglycemia (a blood sugar level thats too low) Allergic reactions Worsening of diabetic retinopathy (eye disease) Acute kidney injury Possible increased risk of pancreatic or thyroid cancer Interactions with other medications Because of the results of animal studies, there has been some concern that semaglutide, liraglutide, and other GLP-1 RAs might increase the risk of certain cancers, including thyroid cancer
Semaglutide produced mixed results in animal models
Novo Nordisk has indicated plans to launch a higher-dose oral version for weight loss in the US market in 2026
F 1.610.650.0170 ADEs may also be reported to the FDA: 1.800.FDA.1088 or www.fda.gov/medwatch Medical Information: T 1.888.354.4855 (9:00 am5:00 pm Eastern Time, MondayFriday) www.americanregent.com/medical-affairs For medical information outside of normal business hours that cannot wait until the next business day, please call 1.877.845.6371 About American Regent American Regent, Inc
For example, patients with certain GLP1R variants may experience stronger appetite suppression at lower doses, suggesting a slower escalation is optimal